In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

One-hour rule-out and rule-in of acute myocardial infarction using a novel high-sensitivity cardiac troponin I assay

Session Poster session 5

Speaker Raphael Twerenbold

Event : ESC Congress 2017

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Non-ST-Elevation Myocardial Infarction (NSTEMI)
  • Session type : Poster Session

Authors : R Twerenbold (Basel,CH), J Boeddinghaus (Basel,CH), T Nestelberger (Basel,CH), M Rubini Gimenez (Basel,CH), C Puelacher (Basel,CH), O Miro (Barcelona,ES), FJ Martin-Sanchez (Madrid,ES), B Morawiec (Katowice,PL), S Osswald (Basel,CH), T Reichlin (Basel,CH), C Mueller (Basel,CH)

Authors:
R. Twerenbold1 , J. Boeddinghaus1 , T. Nestelberger1 , M. Rubini Gimenez1 , C. Puelacher1 , O. Miro2 , F.J. Martin-Sanchez3 , B. Morawiec4 , S. Osswald1 , T. Reichlin1 , C. Mueller1 , 1University Hospital Basel - Basel - Switzerland , 2Hospital Clinic de Barcelona - Barcelona - Spain , 3Hospital Clinic San Carlos - Madrid - Spain , 4Medical University of Silesia, Cardiology department - Katowice - Poland ,

Citation:
European Heart Journal ( 2017 ) 38 ( Supplement ), 1006

Background: The European Society of Cardiology suggests the use of a 0/1h-algorithm for rapid rule-out and rule-in of acute myocardial infarction (AMI) when using high-sensitivity cardiac troponin (hs-cTn).

Purpose: We aimed to derive and validate a new 0/1h-algorithm for a novel hs-cTnI assay.

Methods: In a prospective international multicentre diagnostic study enrolling patients presenting with suspected AMI to the ED, hs-cTnI was determined at baseline and after one hour using Centaur hs-cTnI. Patients presenting with STEMI were excluded. The final diagnosis was centrally adjudicated by two independent cardiologists using all available data including coronary angiography, echocardiography, follow-up data, and serial measurements of hs-cTnT (but not hs-cTnI). The hs-cTnI 0/1h-algorithm, incorporating measurements performed at baseline and absolute changes within 1 hour, was derived in a randomly selected sample of 672 patients (derivation sample) using classification and regression tree (CART) analysis, and then validated in the remaining 675 patients (validation sample).

Results: Acute myocardial infarction was the final diagnosis in 18% of the 1347 recruited patients. After applying the hs-cTnI 0/1h-algorithm developed in the derivation cohort to the validation cohort, 46% of patients could be classified as “rule-out”, 18% as “rule-in”, and 36% as “observe” (Figure 1). In the validation cohort, the derived rule-out strategy resulted in a negative predictive value for AMI of 99.7% (95% confidence interval (CI), 97.8–100%) and a sensitivity of 99.1% (95% CI, 95.3–100%) while the derived rule-in strategy resulted in a positive predictive value for AMI of 72.5% (95% CI, 63.6–80.3%) and a specificity of 94.1% (95% CI, 91.8–95.9%).

Conclusion: Using a simple algorithm incorporating baseline hs-cTnI values and the absolute change within the first hour, measured with a novel hs-cTnI assay, allows very safe rule-out as well as accurate rule-in of AMI in two patients out of three presenting with suspected AMI.

Figure 1

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are